Structure Therapeutics (GPCR) Accounts Payables (2022 - 2026)

Structure Therapeutics' Accounts Payables history runs 5 years deep, the most recent figure standing at $7.8 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 10.2% year-over-year to $7.8 million in Q1 2026; TTM through Mar 2026 was $7.8 million, a 10.2% decrease from a year earlier, with the FY2025 full-year figure at $13.9 million, up 72.78% from the prior year.
• Accounts Payables slipped to $7.8 million in Q1 2026 per GPCR's latest filing, from $13.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $17.8 million in Q3 2025 and bottomed at $2.2 million in Q2 2024.
• The 5-year median for Accounts Payables is $7.2 million (2024), against an average of $7.7 million.
• Across the five-year window, Accounts Payables plunged 61.24% in 2024 and soared 306.97% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $6.0 million in 2022, then decreased by 21.09% to $4.7 million in 2023, then jumped by 69.21% to $8.0 million in 2024, then soared by 72.78% to $13.9 million in 2025, then plunged by 43.58% to $7.8 million in 2026.
• Per Business Quant, the three latest GPCR Accounts Payables figures stand at $7.8 million (Q1 2026), $13.9 million (Q4 2025), and $17.8 million (Q3 2025).